Navigation Links
Authorization for AGENDA Phase 3 Trial of Genasense(R) in Advanced Melanoma Granted by French Regulatory Agency
Date:10/17/2007

um) Injection is the Company's lead compound from its DNA/RNA Medicines program. Genta is currently recruiting patients for a global Phase 3 trial of Genasense in patients with advanced melanoma. The leading drug in Genta's Small Molecule program is Ganite(R) (gallium nitrate injection), which the Company is exclusively marketing in the U.S. for treatment of symptomatic patients with cancer related hypercalcemia that is resistant to hydration. The Company has developed an oral formulation of the active ingredient in Ganite that is currently undergoing initial clinical trials as a potential treatment for diseases associated with accelerated bone loss. Genta is partnered with IDIS (http://www.idispharma.com) on a program whereby both Ganite(R) and Genasense(R) are available on a "named-patient" basis in countries outside the United States. For more information about Genta, please visit our website at: http://www.genta.com.

Safe Harbor

This press release may contain forward-looking statements with respect to business conducted by Genta Incorporated. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Forward- looking statements include, without limitation, statements about:

-- the Company's ability to obtain necessary regulatory approval for

Genasense(R) from the U.S. Food and Drug Administration ("FDA") or

European Medicines Agency ("EMEA");

-- the safety and efficacy of the Company's products or product

candidates;

-- the Company's assessment of its clinical trials;

-- the commencement and completion of clinical trials;

-- the Company's ability to develop, manufacture, license and sell its

products or product candidates;

-- the Company's ability to
'/>"/>

SOURCE Genta Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... Aug. 3, 2015  CytRx Corporation (NASDAQ: CYTR ... oncology, today reported financial results for the three months ... of recent accomplishments and upcoming milestones for its clinical ... has been very productive for CytRx. Enrollment in our ... in soft tissue sarcoma (STS) continues on track to ...
(Date:8/3/2015)... Aug. 3, 2015 Merrimack Pharmaceuticals, Inc. (Nasdaq: ... its Second Quarter 2015 Investor Conference Call and webcast ... The call will cover an update on Merrimack,s ... 2015 financials. A press release detailing the information to ... afternoon of Monday, August 10. Investors and the general ...
(Date:8/3/2015)... , Aug. 3, 2015  Celsion Corporation ... Company will host a conference call to discuss ... an update on its development programs for ThermoDox®, ... two newly acquired technology platforms, TheraPlas™ and TheraSilence™, ... EDT on Monday, August 10, 2015. To participate ...
Breaking Medicine Technology:CytRx Reports 2015 Second Quarter Financial Results 2CytRx Reports 2015 Second Quarter Financial Results 3CytRx Reports 2015 Second Quarter Financial Results 4CytRx Reports 2015 Second Quarter Financial Results 5CytRx Reports 2015 Second Quarter Financial Results 6CytRx Reports 2015 Second Quarter Financial Results 7CytRx Reports 2015 Second Quarter Financial Results 8CytRx Reports 2015 Second Quarter Financial Results 9CytRx Reports 2015 Second Quarter Financial Results 10CytRx Reports 2015 Second Quarter Financial Results 11CytRx Reports 2015 Second Quarter Financial Results 12CytRx Reports 2015 Second Quarter Financial Results 13CytRx Reports 2015 Second Quarter Financial Results 14Merrimack Pharmaceuticals Announces Timing of Second Quarter 2015 Investor Conference Call 2Celsion Corporation to Hold Second Quarter 2015 Financial Results Conference Call on Monday, August 10, 2015 2
... BETHLEHEM, Pa., Jan. 3, 2012  Particle Sciences, a leading ... module to its DOSE™ program.  The DOSE™ program ... modeling tools to efficiently arrive at the optimal ... form.  Previously, Particle Sciences implemented software solutions for ...
... Institute ( www.ecri.org ), an independent nonprofit that ... listed 10 health technology issues that hospital leaders ... The just-released list takes into account the convergence ... currently facing healthcare executives. (Photo:  ...
Cached Medicine Technology:Particle Sciences Expands Its DOSE™ Program With Additional Proprietary Modeling Capabilities 2ECRI Institute Puts 10 Technology Issues on its 2012 Watch List for Hospital Executives 2ECRI Institute Puts 10 Technology Issues on its 2012 Watch List for Hospital Executives 3ECRI Institute Puts 10 Technology Issues on its 2012 Watch List for Hospital Executives 4
(Date:8/3/2015)... ... August 03, 2015 , ... Web SEO Master offers the most affordable web design and ... problem - making the most out of their dollar. Every company that is starting ... crucial for existence. But not only does a start up need to be online, ...
(Date:8/3/2015)... ... 03, 2015 , ... sweetFrog Enterprises, LLC. is pleased to announce the reopening ... operating in the Lone Star State. The premium frozen yogurt chain was listed as ... store, located at 2916 US-75, Sherman, TX 38652, will have grand opening festivities this ...
(Date:8/3/2015)... ... August 03, 2015 , ... Code , an industry leader ... , a Bluetooth Code Reader accessory that enables a wireless connection between the ... helps enable a variety of barcode reading applications with iPads, Galaxy Tabs, and many ...
(Date:8/3/2015)... ... August 03, 2015 , ... According to an opinion piece published July 28 ... leads to one pound of weight loss may not be accurate. While this system may ... one pound of fat varies – based both on the individual and at what point ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... Appeals ruled in favor of the firm’s client Rebecca Hamsher, deciding that in ... Center must reimburse benefits for Hamsher’s residential treatment for bulimia, depression and other ...
Breaking Medicine News(10 mins):Health News:Web SEO Master, a division of SH Web Design & SH Web Commerce, Inc. begins offering Web Design and SEO Services for Start Up Companies located in Indianapolis, Indiana 2Health News:Web SEO Master, a division of SH Web Design & SH Web Commerce, Inc. begins offering Web Design and SEO Services for Start Up Companies located in Indianapolis, Indiana 3Health News:sweetFrog Reopens Texas Store Today 2Health News:Code Launches the T500, an Innovative Code Reader Accessory 2Health News:Code Launches the T500, an Innovative Code Reader Accessory 3Health News:Article Dispelling Weight Loss Myth Correctly Emphasizes the Complicated and Difficult Nature of Weight Loss, Says Dr. Michael Feiz 2Health News:Kantor & Kantor Announces North Cypress Medical Center Must Reimburse Benefits for Mental Health Treatment 2Health News:Kantor & Kantor Announces North Cypress Medical Center Must Reimburse Benefits for Mental Health Treatment 3
... has shown that women with breast cancer who are active ... to those,who lead a sedentary lifestyle. Evidence from various studies ... who are physically active. This study analyzed the responses from ... stage I, II, II breast cancer. These nurses were diagnosed ...
... can affect your memory and your learning //capabilities. ... alcohol daily for even as less as eight weeks ... learning. Researchers from St. Louis University School of Medicine ... cognitive impairment can remain even after quitting drinking. ...
... compression stockings that are worn during long hours of flying ... ,Researchers of the study had compared nine studies of nearly ... researchers had carried out the research where they had advised ... regularly, drink water, avoid salty food and do not stop ...
... have shown that twisting the graft to bypass a blockage ... ,In using a graft to bypass blockages, scientists often ... patients with renal problems have dialysis. This is called a ... as in the blood vessels, the blood flows twisting and ...
... The toxin called ACV1 is being tested on humans as ... Bruce Livett and team from the Department of Biochemistry and ... University of Melbourne, and Bio21 Research Institute, the toxin has ... ,The toxin is produced in the venom of marine ...
... interesting prospective study undertaken by the,researchers at Massachusetts General ... that ,higher intake of low-fat dairy may lower the ... type 2 diabetes, either the body does not produce,enough ... for the body to be able to use,sugar. Type ...
Cached Medicine News:
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: